Atobegron

Atobegron is a small molecule beta-3 adrenergic receptor agonist developed and marketed by Atco Pharma, an Egyptian pharmaceutical company. It is indicated for the treatment of urogenital conditions, specifically overactive bladder (OAB) and urinary incontinence. By selectively targeting and activating beta-3 adrenergic receptors in the detrusor muscle of the bladder, Atobegron promotes bladder relaxation during the storage phase of the micturition cycle. This mechanism increases bladder capacity and reduces the frequency of involuntary contractions, offering a therapeutic alternative to traditional antimuscarinic agents with a reduced risk of typical side effects such as dry mouth and constipation. Atobegron represents a key component of Atco Pharma's urology portfolio and their expansion into specialized therapeutic areas.

Brand names

Atobegron